Published in Allergy Asthma Clin Immunol on September 15, 2006
Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol (2001) 7.27
Intranasal exposure to protein antigen induces immunological tolerance mediated by functionally disabled CD4+ T cells. J Immunol (1999) 1.77
Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy (1986) 1.71
Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol (1998) 1.70
Tregs and allergic disease. J Clin Invest (2004) 1.64
Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers. Clin Exp Allergy (2001) 1.50
Mechanisms of immunotherapy. J Allergy Clin Immunol (2004) 1.45
Local immunotherapy is not documented for clinical use. Allergy (1994) 1.43
Decrease of allergen-specific T-cell response induced by local nasal immunotherapy. Clin Exp Allergy (1998) 1.42
Nasal immunotherapy to Parietaria: evidence of reduction of local allergic inflammation. Am J Respir Crit Care Med (1995) 1.40
Changes in nasal airways resistance on antigenic challenge in allergic rhinitis. Clin Allergy (1971) 1.34
CSM Update: Desensitising vaccines. Br Med J (Clin Res Ed) (1986) 1.09
Suppression of IgE responses by passive antigen inhalation: dissociation of local (mucosal) and systemic immunity. Cell Immunol (1987) 0.93
Suppression of allergen reactive Th2 mediated responses and pulmonary eosinophilia by intranasal administration of an immunodominant peptide is linked to IL-10 production. Vaccine (2003) 0.90
Nasal mucosal hyperpermeability to macromolecules in atopic rhinitis and extrinsic asthma. J Allergy Clin Immunol (1975) 0.89
Local intranasal immunotherapy for grass-allergic rhinitis. J Allergy Clin Immunol (1983) 0.85
Low-dose local nasal immunotherapy in children with perennial allergic rhinitis due to Dermatophagoides. Allergy (2002) 0.84
Intranasal treatment with ovalbumin but not the major T cell epitope ovalbumin 323-339 generates interleukin-10 secreting T cells and results in the induction of allergen systemic tolerance. Clin Exp Allergy (2004) 0.84
Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. J Allergy Clin Immunol (1997) 0.82
Suppression of IgE responses following inhalation of antigen A natural homeostatic mechanism which limits sensitization to aeroallergens. Immunol Today (1987) 0.81
Local immunotherapy. Allergy (1998) 0.81
A double-blind, placebo-controlled trial of local nasal immunotherapy in allergic rhinitis to Parietaria pollen. Clin Exp Allergy (1995) 0.80
Local nasal desensitization in allergic rhinitis. Clin Allergy (1972) 0.80
Use of glutaraldehyde-modified timothy grass pollen extract in nasal hyposensitisation treatment of hay fever. Int Arch Allergy Appl Immunol (1979) 0.80
Allergen-specific nasal challenge: response kinetics of clinical and inflammatory events to rechallenge. Int Arch Allergy Immunol (1998) 0.80
Local nasal immunotherapy: efficacy and tolerability of two different administration schedules in grass pollen rhinitis. Allergol Immunopathol (Madr) (2000) 0.79
Local nasal immunotherapy for Dermatophagoides-induced rhinitis: efficacy of a powder extract. J Allergy Clin Immunol (1993) 0.79
Preseasonal intranasal immunotherapy with nebulized short ragweed extract. J Allergy Clin Immunol (1981) 0.79
Further evaluation of local intranasal immunotherapy with aqueous and allergoid grass extracts. J Allergy Clin Immunol (1984) 0.79
Nasal immunotherapy in weed-induced allergic rhinitis. Ann Allergy Asthma Immunol (1997) 0.79
Local nasal immunotherapy with a powder extract for grass pollen induced rhinitis in pediatric ages: a controlled study. J Investig Allergol Clin Immunol (1997) 0.78
Local nasal immunotherapy and bronchial hyperreactivity in seasonal allergic rhinitis: an observational pilot study. J Investig Allergol Clin Immunol (2001) 0.78
Nasal immunotherapy at constant dosage: a double-blind, placebo-controlled study in grass-allergic rhinoconjunctivitis. J Investig Allergol Clin Immunol (2001) 0.78
Local intranasal immunotherapy for ragweed allergic rhinitis. I. Clinical response. J Allergy Clin Immunol (1981) 0.78
Pharmacokinetics of radiolabelled Par j 1 administered intranasally to allergic and healthy subjects. Clin Exp Allergy (2005) 0.78
Clinical efficacy and tolerability of a steady dosage schedule of local nasal immunotherapy. Results of preseasonal treatment in grass pollen rhinitis. Ann Allergy Asthma Immunol (1999) 0.77
Long-term follow-up of nasal immunotherapy to Parietaria: clinical and local immunological effects. Clin Exp Allergy (1997) 0.77
Local nasal immunotherapy in allergic rhinitis to Parietaria. A double-blind controlled study. Allergy (1992) 0.77
Local nasal immunotherapy with extract in powder form is effective and safe in grass pollen rhinitis: a double-blind study. J Allergy Clin Immunol (1996) 0.77
Preseasonal intranasal immunotherapy in birch-alder allergic rhinitis. A double-blind study. Allergy (1996) 0.77
Nasal hyposensitization and hay fever. Clin Allergy (1975) 0.76
Detection of IgE-binding activity in serum after intranasal treatment of normal rabbits with P. judaica extract. Allergy (1991) 0.76
Airways of allergic rhinitics are 'primed' to repeated allergen inhalation challenge. Clin Exp Allergy (1994) 0.76
Intranasal immunotherapy and polymerized grass pollen allergens. Allergy (1982) 0.76
Symptomatic relief after grass nasal immunotherapy: lasting efficacy after 4-5 years. J Investig Allergol Clin Immunol (2003) 0.76
Nasal immunotherapy is effective in the treatment of rhinitis due to mite allergy. A double-blind, placebo-controlled study with rhinological evaluation. Int J Immunopathol Pharmacol (2003) 0.76
A multicenter trial of specific local nasal immunotherapy. Laryngoscope (2000) 0.76
Local nasal immunotherapy for birch allergic rhinitis with extract in powder form. Clin Exp Allergy (1995) 0.76
Pharmacokinetics of allergens after local administration. Allergy (1997) 0.76
Intranasal immunotherapy with Dermatophagoides extract: in vivo and in vitro results of a double-blind placebo-controlled trial. Rhinology (1995) 0.76
Efficacy and safety of rupatadine for allergic rhino-conjunctivitis: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis. Curr Med Res Opin (2013) 1.92
Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest (2007) 1.84
A review of the evidence from comparative studies of levocetirizine and desloratadine for the symptoms of allergic rhinitis. Clin Ther (2005) 1.45
Why do doctors and patients not follow guidelines? Curr Opin Allergy Clin Immunol (2009) 1.35
Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol (2013) 1.33
Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol (2006) 1.26
Quality of life in Duchenne muscular dystrophy: the subjective impact on children and parents. J Child Neurol (2011) 1.13
Possible role of climate changes in variations in pollen seasons and allergic sensitizations during 27 years. Ann Allergy Asthma Immunol (2010) 1.13
The link between allergic rhinitis and asthma: the united airways disease. Expert Rev Clin Immunol (2010) 1.11
Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol (2007) 1.11
The ImmunoCAP ISAC molecular allergology approach in adult multi-sensitized Italian patients with respiratory symptoms. Clin Biochem (2011) 1.08
Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol (2010) 1.06
Bridging allergologic and botanical knowledge in seasonal allergy: a role for phenology. Ann Allergy Asthma Immunol (2010) 1.04
Perturbations of natural killer cell regulatory functions in respiratory allergic diseases. J Allergy Clin Immunol (2007) 0.98
Clara cell 16 protein in COPD sputum: a marker of small airways damage? Respir Med (2007) 0.97
How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint. J Allergy Clin Immunol (2010) 0.94
Specific immunotherapy for respiratory allergy: state of the art according to current meta-analyses. Ann Allergy Asthma Immunol (2009) 0.93
Allergic diseases and their impact on quality of life. Ann Allergy Asthma Immunol (2006) 0.92
Quantitative assessment of the adherence to sublingual immunotherapy. J Allergy Clin Immunol (2004) 0.90
Human lung myofibroblasts as effectors of the inflammatory process: the common receptor gamma chain is induced by Th2 cytokines, and CD40 ligand is induced by lipopolysaccharide, thrombin and TNF-alpha. Eur J Immunol (2002) 0.89
Allergen-specific immunotherapy in asthmatic children: from the basis to clinical applications. Expert Rev Vaccines (2013) 0.89
Asthma management failure: a flaw in physicians' behavior or in patients' knowledge? J Asthma (2011) 0.88
New insights into airway remodelling in asthma and its possible modulation. Curr Opin Allergy Clin Immunol (2008) 0.87
Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study. Ann Allergy Asthma Immunol (2006) 0.86
Disability in COPD and its relationship to clinical and patient-reported outcomes. Curr Med Res Opin (2011) 0.86
Asthma mortality, inhaled steroids, and changing asthma therapy in Argentina (1990-1999). Respir Med (2005) 0.86
Patient knowledge, perceptions, expectations and satisfaction on allergen-specific immunotherapy: a survey. Respir Med (2012) 0.86
Sublingual Immunotherapy: Clinical Indications in the WAO-SLIT Position Paper. World Allergy Organ J (2010) 0.85
A review of the use of fluticasone furoate since its launch. Expert Opin Pharmacother (2011) 0.84
Office spirometry can improve the diagnosis of obstructive airway disease in primary care setting. Respir Med (2009) 0.84
The clinical characteristics of respiratory allergy in immigrants in northern Italy. Int Arch Allergy Immunol (2008) 0.84
Harmful effect of immunotherapy in children with combined snail and mite allergy. J Allergy Clin Immunol (2002) 0.84
Pharmacokinetics of Der p 2 allergen and derived monomeric allergoid in allergic volunteers. Int Arch Allergy Immunol (2005) 0.84
Clinical and cytologic characteristics of allergic rhinitis in elderly patients. Ann Allergy Asthma Immunol (2012) 0.84
Sublingual immunotherapy for allergic rhinitis and conjunctivitis. Immunotherapy (2013) 0.83
Patients with asthma and comorbid allergic rhinitis: is optimal quality of life achievable in real life? PLoS One (2012) 0.83
Treatment of acquired cold urticaria with cetirizine and zafirlukast in combination. J Am Acad Dermatol (2003) 0.83
The possible influence of the environment on respiratory allergy: a survey on immigrants to Italy. Ann Allergy Asthma Immunol (2011) 0.83
Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized controlled study. J Allergy Clin Immunol (2005) 0.83
When allergic rhinitis is not only allergic. Am J Rhinol Allergy (2009) 0.82
The relationship between asthma control and quality-of-life impairment due to chronic cough: a real-life study. Ann Allergy Asthma Immunol (2008) 0.82
Biomarker discovery in asthma and COPD by proteomic approaches. Proteomics Clin Appl (2014) 0.82
Serum cytotoxic T lymphocyte-associated antigen 4 in Hymenoptera venom allergy and its modulation by specific immunotherapy. J Allergy Clin Immunol (2008) 0.82
Chronic obstructive pulmonary disease patient well-being and its relationship with clinical and patient-reported outcomes: a real-life observational study. Respiration (2011) 0.82
Allergy training and immunotherapy in Latin America: results of a regional overview. Ann Allergy Asthma Immunol (2013) 0.82
Airway remodelling in children: when does it start? Curr Opin Allergy Clin Immunol (2007) 0.81
Molecular allergy diagnosis: we need to become more knowledgeable. Ann Allergy Asthma Immunol (2012) 0.81
Component-resolved diagnosis in pediatric allergic rhinoconjunctivitis and asthma. Curr Opin Allergy Clin Immunol (2013) 0.81
The safety of allergen specific sublingual immunotherapy. Curr Drug Saf (2007) 0.81
Impact of bariatric surgery on pulmonary function and nitric oxide in asthmatic and non-asthmatic obese patients. J Asthma (2011) 0.81
Obstructive lung diseases and inhaler treatment: results from a national public pragmatic survey. Respir Res (2013) 0.80
Effects of fexofenadine and other antihistamines on components of the allergic response: adhesion molecules. J Allergy Clin Immunol (2003) 0.80
Eosinophilic esophagitis: which role for food and inhalant allergens? Asia Pac Allergy (2012) 0.80
Focus on cat allergen (Fel d 1): immunological and aerodynamic characteristics, modality of airway sensitization and avoidance strategies. Int Arch Allergy Immunol (2003) 0.80
Safety and tolerability of sublingual immunotherapy in clinical trials and real life. Curr Opin Allergy Clin Immunol (2013) 0.80
Cross-sectional comparison of the characteristics of respiratory allergy in immigrants and Italian children. Pediatr Allergy Immunol (2014) 0.80
Emerging drugs for allergic conjunctivitis. Expert Opin Emerg Drugs (2014) 0.80
Oral and sublingual immunotherapy in paediatric patients. Curr Opin Allergy Clin Immunol (2003) 0.80
Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy. Ann Allergy Asthma Immunol (2008) 0.80
Sublingual immunotherapy: update 2006. Curr Opin Allergy Clin Immunol (2006) 0.79
Non-injection routes for allergen immunotherapy: focus on sublingual immunotherapy. Inflamm Allergy Drug Targets (2006) 0.79
Development and validation of the Drug Hypersensitivity Quality of Life Questionnaire. Ann Allergy Asthma Immunol (2011) 0.79
Emerging sublingual immunotherapy drugs. Expert Opin Pharmacother (2010) 0.79
Administration of a polyvalent mechanical bacterial lysate to elderly patients with COPD: Effects on circulating T, B and NK cells. Immunol Lett (2012) 0.79
The role of Pneumococcal vaccine. Pulm Pharmacol Ther (2008) 0.78
Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety. Expert Rev Clin Immunol (2014) 0.78
May we strengthen the human natural defenses with bacterial lysates? World Allergy Organ J (2010) 0.78
Pitfalls in respiratory allergy management: alexithymia and its impact on patient-reported outcomes. J Asthma (2010) 0.78
Advances in allergen-specific immunotherapy. Curr Drug Targets (2009) 0.78
Effects of different up-dosing regimens for hymenoptera venom immunotherapy on serum CTLA-4 and IL-10. PLoS One (2012) 0.78
Sublingual immunotherapy: other indications. Immunol Allergy Clin North Am (2011) 0.78
An update on the asthma-rhinitis link. Curr Opin Allergy Clin Immunol (2004) 0.78
Coping with asthma: is the physician able to identify patient's behaviour? Respir Med (2012) 0.77
Efficacy and safety of sublingual immunotherapy. Ann Allergy Asthma Immunol (2004) 0.77
Randomized open comparison of the safety of SLIT in a no-updosing and traditional updosing schedule in patients with Parietaria allergy. Allergol Immunopathol (Madr) (2006) 0.77
A model of allergen-driven human airway contraction: beta2 pathway dysfunction without cytokine involvement. Ann Allergy Asthma Immunol (2005) 0.77
Levocetirizine in the treatment of allergic diseases. Expert Opin Pharmacother (2009) 0.77
Safety profile of sublingual immunotherapy. Treat Respir Med (2006) 0.77
Long-acting bronchodilators improve health related quality of life in patients with COPD. Respir Med (2013) 0.77
Disability in moderate chronic obstructive pulmonary disease: prevalence, burden and assessment - results from a real-life study. Respiration (2015) 0.77
Sublingual immunotherapy: an update. Curr Opin Allergy Clin Immunol (2004) 0.77
Sublingual immunotherapy: where do we stand? Present and future. Curr Opin Allergy Clin Immunol (2009) 0.77
Immunotherapy in polysensitized patients: new chances for the allergists? Ann Allergy Asthma Immunol (2012) 0.76
Medical treatment reverses cytokine pattern in allergic and nonallergic chronic rhinosinusitis in asthmatic children. Pediatr Allergy Immunol (2003) 0.76
Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due to grass pollen. Ann Allergy Asthma Immunol (2009) 0.76
Will sublingual immunotherapy offer benefit for asthma? Curr Allergy Asthma Rep (2013) 0.76
Sublingual immunotherapy for allergic respiratory diseases: efficacy and safety. Immunol Allergy Clin North Am (2011) 0.76
Pharmacotherapy of allergic rhinitis: current options and future perspectives. Expert Opin Pharmacother (2013) 0.76
A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma. Int Arch Allergy Immunol (2016) 0.76
Specific immunotherapy with allergens: an important tool in the treatment of the allergic diseases. J Dtsch Dermatol Ges (2012) 0.76
Comparison of the effects in the nose and skin of a single dose of desloratadine and levocetirizine over 24 hours. Int Arch Allergy Immunol (2004) 0.76
The relationship between allergen immunotherapy and omalizumab for treating asthma. Expert Rev Respir Med (2015) 0.75
Re Letter to the editor re: Compalati E, Canonica GW. Efficacy and safety of rupatadine for allergic rhinoconjunctivitis: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis. Curr Med Res Opin 2013 Jul 5. Curr Med Res Opin (2013) 0.75
Disease-modifying effect and economic implications of sublingual immunotherapy. J Allergy Clin Immunol (2010) 0.75
Is health-related quality of life associated with upper and lower airway inflammation in asthmatics? Biomed Res Int (2013) 0.75
DRACMA one year after: which changes have occurred in diagnosis and treatment of CMA in Italy? Ital J Pediatr (2011) 0.75
Sublingual immunotherapy for Alternaria-induced allergic rhinitis: a randomized placebo-controlled trial. Ann Allergy Asthma Immunol (2010) 0.75
Targeted therapy for allergic asthma: predicting and evaluating response to omalizumab. Expert Rev Clin Immunol (2007) 0.75
Molecular diagnosis and precision medicine in allergy management. Clin Chem Lab Med (2016) 0.75
Randomized open comparison of montelukast and sublingual immunotherapy as add-on treatment in moderate persistent asthma due to birch pollen. J Investig Allergol Clin Immunol (2010) 0.75